All In Biotech

Drug Trial Radar · NCT05296733

A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906

A Non-randomised, Open-label, 2-part, Parallel-cohort Trial to Evaluate 1) Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of BI 456906 in Patients With Cirrhosis and Varying Degrees of Hepatic Impairment Relative to Healthy Subjects With and Without Overweight/Obesity and 2) Safety and Tolerability of Multiple Subcutaneous Doses of BI 456906 in Patients With Overweight/Obesity With Cirrhosis and Varying Degrees of Hepatic Impairment Relative to Patients With Overweight/Obesity Without Cirrhosis/Hepatic Impairment

Last checked: Nov 19, 2026Latest source record: Aug 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

82

Actual

Start

Apr 27, 2022

Primary completion

Dec 29, 2023

Study completion Dec 29, 2023

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Mar 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults who have different levels of liver problems and adults who are healthy. People with or without overweight or obesity can take part. This study has 2 parts. The purpose of Part 1 is to find out whether having liver problems influences how BI 456906 is taken up in the body. The purpose of Part 2 is to find out whether having liver problems influences how people with overweight and obesity tolerate different doses of BI 456906. In Part 1, participants get a single injection of BI 456906 under their skin and stay at the study site for 2 nights afterwards. They are in the study for about a month. During this time, they visit the study site about 8 more times. The doctors compare the amount of BI 456906 in the blood of healthy people and people with liver problems. In Part 2, participants get 1 or 2 injections of BI 456906 once a week under their skin for 28 weeks. At the beginning, they get lower doses of BI 456906. Over time, they get higher doses until they reach a certain dose of BI 456906. This dose is then maintained until the end of the treatment. Participants in Part 2 are in the study for about 7 months. During this time, they visit the study site about 16 times and get about 15 phone calls from the site staff. The doctors record the number of people with health problems that could have been caused by treatment with BI 456906. They compare the results between participants with liver problems and those without liver problems. In both parts, doctors also regularly check participants' health and take note of any unwanted effects.

Conditions

  • Healthy
  • Liver Diseases
  • Obesity

Interventions

  • BI 456906Drug

    BI 456906

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Area under the concentration-time curve of BI 456906 in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)Time frame: Up to 360 hours
  2. Part A: Maximum measured concentration of BI 456906 in plasma (Cmax)Time frame: Up to 360 hours
  3. Part B: Percentage of patients treated who experience treatment-emergent adverse eventTime frame: Up to Day 218

Locations

13 sites in 6 countries. Site status is shown where the registry gives one.

  • Arizona Liver Health

    Chandler, Arizona

  • Covenant Metabolic Specialists, LLC

    Fort Myers, Florida

  • Covenant Metabolic Specialists, LLC

    Sarasota, Florida

  • American Research Corporation at the Texas Liver Institute

    San Antonio, Texas

  • IMA Clinical Research San Antonio

    San Antonio, Texas

  • Universitätsklinikum Bonn AöR

    Bonn, Germany

  • Universitätsklinikum Hamburg-Eppendorf

    Hamburg, Germany

  • Universitätsklinikum Ulm

    Ulm, Germany

  • Semmelweis University

    Budapest, Hungary

  • CRU Hungary Ltd.

    Kistarcsa, Hungary

  • New Zealand Clinical Research (NZCR)

    Auckland, New Zealand

  • Dr. Piotr Napora, Center of Clinical Research

    Wroclaw, Poland

  • SUMMIT CLINICAL RESEARCH, s.r.o.

    Bratislava, Slovakia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.